5th March 2015

ATL1103 Higher Dose Study to Support Phase III to Commence

Antisense Therapeutics (ASX:ANP or "the Company") is pleased to advise that it has received the requisite approvals and acknowledgements to commence patient enrolment in its planned ATL1103 higher dose study in patients with the growth disorder acromegaly.

This follow-on study to the previously reported successful Phase II trial of ATL1103 is being conducted in Australia to support its use in dose escalation in patients with more active disease during a Phase III clinical trial. The data collected to date indicate that a higher dose of ATL1103 administered for longer periods of time should be sufficiently well tolerated and potentially may be even more effective resulting in normalization of IGF-I in a significant percentage of acromegaly patients.

As previously announced, this additional higher dose study is being conducted in parallel with the Company's partnering process which continues (as outlined in ANP's "Company Update" ASX announcement 9 December 2014), with the view that this study will add further value to ATL1103 ahead of Phase III registration trials.

Patients recruited for this trial will be screened to confirm eligibility during a 28 day period after which dosing will commence. Some patients may also need to "washout" any current acromegaly medications for a period of 6 weeks to 4 months, depending on the type of medication, before dosing with ATL1103 can begin. The Company is currently estimating that enrolment and dosing would be completed by the end of calendar 2015 with the primary efficacy results available soon after.

The design of this higher dose trial is an open-label study of the safety, tolerability, pharmacokinetics and efficacy [effect on serum insulin like growth factor I (sIGF-I)] of ATL1103 in adult patients with acromegaly dosed twice weekly with ATL1103 at 300mg for 13 weeks (600mg weekly) with two months of follow up.

The relatively low cost study is eligible for the 45% R&D Tax incentive refund.

Contact Information:
Website: www.antisense.com.au
Managing Director: Mark Diamond +61 (0)3 9827 8999
Australian Investor/Media: Annabel Murphy+61 (0)2 9237 2800; amurphy@buchanwe.com.au

Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for large unmet markets. ANP has 4 products in its development pipeline that it has in-licensed from Isis Pharmaceuticals Inc., world leaders in antisense drug development and commercialisation - ATL1102 (injection) which has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS) , ATL1103 drug designed to block GHr production which in a Phase II clinical trial, successfully reduced blood IGF-I levels in patients with the growth disorder acromegaly, ATL1102 (inhaled) which is at the pre-clinical research stage as a potential treatment for asthma and ATL1101 a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for cancer.